VIFN Vifor Pharma AG

Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously

Regulatory News:

This press release features multimedia. View the full release here:

Iron Deficiency Day is an international event which raises awareness of the serious impact of iron deficiency and iron deficiency anaemia.1

Since its launch in 2015, Iron Deficiency Day has aimed to educate people globally about the importance of iron for the body and what can happen if iron levels are not properly managed. It encourages people to become better informed and take control over their health.

Iron deficiency and iron deficiency anaemia is estimated to affect one in three people worldwide2, yet despite the serious consequences and high prevalence of iron deficiency,3 it is still an under-recognised condition.

Stefan Schulze, President of the Executive Committee and COO from Vifor Pharma said: “At Vifor Pharma we strive to help patients around the world lead better and healthier lives. We are very proud that we are able to join forces with The Heart Failure Policy Network, European Kidney Health Alliance and the Anaemia Community to raise global awareness of the serious health problems associated with iron deficiency and iron deficiency anaemia.”

Iron deficiency, with and without anaemia, can be debilitating and exacerbate underlying chronic diseases, leading to increased morbidity and mortality.4 The symptoms of iron deficiency can manifest in different ways; they are hard to determine and can be associated with a number of other health conditions4,5, but common symptoms include:

  • Fatigue
  • Pale skin
  • Brittle nails
  • Inability to concentrate

Iron Deficiency Day 2019 has a particular focus on the importance of iron deficiency in women’s health, and the connection between iron deficiency and chronic heart failure.

Ed Harding of the European Heart Failure Policy Network said: “Iron deficiency in conditions such as heart failure is a very serious problem; in Europe 50% of CHF Patients have some form of iron deficiency6. Iron Deficiency Day has an important role in raising awareness of these conditions and helping people to understand their symptoms, seek a proper diagnosis, and ultimately receive the correct treatment.”

For more information visit the Iron Deficiency Day website at and follow on Instagram and on Twitter, using the hashtags #IDDay2019 #TakeIronSeriously #IronDeficiency #IronMatters.

Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

Notes to Editors

.

The site features all the campaign materials including the symptom cartoon characters, Symptom Checker which will use animations to explain the most common effects of iron deficiency and iron deficiency anaemia in order to educate people in recognising the condition and seek help. In addition patient testimonials and links to social media are also available.

As well as in English, the Iron Deficiency Day website is available in German, French, Spanish, Greek, Romanian, Russian, Arabic, Portuguese, and Italian.

About iron deficiency

Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five.7 Left untreated, it can develop into iron deficiency anaemia. The effects of iron deficiency differ from person to person, but can be linked to an overall decline in general health and well-being.8 Even without anaemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality.4 Common symptoms include fatigue,5, 9, 10 pale skin,5 brittle nails,5, 11 craving non-food items such as dirt, clay and ice, 12 and an inability to concentrate.9, 8 In children, iron deficiency can significantly impair cognitive and motor development.13

References

1. Hassan, Tamer Hasan et al. “Impact of Iron Deficiency Anemia on the Function of the Immune System in Children.” Ed. Esaki M. Shankar. Medicine 95.47 (2016): e5395. PMC. Web. 12 June 2018.

2. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.

3. World Health Organisation. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: . Last accessed: June 2018.

4. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.

5. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.

6. Ebner N, von Haehling S. Iron deficiency in heart failure: a practical guide. Nutrients. 2013;5(9):3730-9. doi:10.3390/nu5093730.

7. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).

8. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.

9. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.

10. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014. <

11. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.

12. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.

13. World Health Organisation. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: . Last accessed: June 2018.

EN
26/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vifor Pharma AG

Life Sciences & Chemicals Team
  • Life Sciences & Chemicals Team

ODDO : Defensive growth sectors

We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...

SN. SMITH & NEPHEW PLC
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG
CVVTF COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
Life Sciences & Chemicals Team
  • Life Sciences & Chemicals Team

ODDO : Defensive growth sectors

We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...

SN. SMITH & NEPHEW PLC
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG
CVVTF COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
 PRESS RELEASE

Cancellation of remaining publicly held registered shares of Vifor Pha...

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share"). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court. Vifor further announced today that SIX Exchange Regulation AG h...

 PRESS RELEASE

Ferinject® approved in Chinafor the treatment of iron deficiency in ad...

ST. GALLEN, Switzerland & BEIJING--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide. “We...

 PRESS RELEASE

Approval of extension of exemptions from SIX disclosure and publicity ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor Pharma AG's ad hoc announcement of August 2, 2022). The relevant parts of the decision of SER of October 19, 2022, are as follows: "I. Die Vifor Pharma AG (Emittent) wird im Hinblick auf die geplante Dekotierung bis und m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch